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Abstract
Blockade of prostaglandin (PG) production by COX inhibitors is the treatment of choice for
inflammatory pain but is also prone to severe side effects. Identification of signaling elements
downstream of COX inhibition, particularly of PG receptor subtypes responsible for pain sensitization
(hyperalgesia), provides a strategy for better-tolerated analgesics. Here, we have identified PGE2
receptors of the EP2 receptor subtype as key signaling elements in spinal inflammatory hyperalgesia.
Mice deficient in EP2 receptors (EP2-/- mice) completely lack spinal PGE2-evoked hyperalgesia. After
a peripheral inflammatory stimulus, EP2-/- mice exhibit only short-lasting peripheral hyperalgesia but
lack a second sustained hyperalgesic phase of spinal origin. Electrophysiological recordings identify
diminished synaptic inhibition of excitatory dorsal horn neurons as the dominant source of EP2
receptor-dependent hyperalgesia. Our results thus demonstrate that inflammatory hyperalgesia can be
treated by targeting of a single PG receptor subtype and provide a rational basis for new analgesic
strategies going beyond COX inhibition.
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Blockade of prostaglandin (PG) production by COX inhibitors is the treatment of choice for inflammatory 
pain but is also prone to severe side effects. Identification of signaling elements downstream of COX inhibi-
tion, particularly of PG receptor subtypes responsible for pain sensitization (hyperalgesia), provides a strategy 
for better-tolerated analgesics. Here, we have identified PGE2 receptors of the EP2 receptor subtype as key 
signaling elements in spinal inflammatory hyperalgesia. Mice deficient in EP2 receptors (EP2–/– mice) com-
pletely lack spinal PGE2-evoked hyperalgesia. After a peripheral inflammatory stimulus, EP2–/– mice exhibit 
only short-lasting peripheral hyperalgesia but lack a second sustained hyperalgesic phase of spinal origin. 
Electrophysiological recordings identify diminished synaptic inhibition of excitatory dorsal horn neurons as 
the dominant source of EP2 receptor–dependent hyperalgesia. Our results thus demonstrate that inflamma-
tory hyperalgesia can be treated by targeting of a single PG receptor subtype and provide a rational basis for 
new analgesic strategies going beyond COX inhibition.
Introduction
Classical COX inhibitors, also known as NSAIDs, are among the 
most frequently used analgesics (for a review see ref. 1). They inhib-
it PG synthesis through nonselective blockade of constitutively 
expressed COX-1 and inducible COX-2 and display, in addition to 
their analgesic effect, antiinflammatory and antipyretic properties. 
Unfortunately, in particular their long-term use is often hampered 
by severe side effects, including gastric ulcerations. It is generally 
accepted that both their desired and their unwanted (side) effects 
originate from the global block of PG production. More recently 
developed COX-2–selective inhibitors (or coxibs) proved analge-
sic and antiinflammatory both in experimental models (2) and in 
patients (e.g., ref. 3). However, recent evidence suggests that the 
prolonged use of these COX-2–selective inhibitors also confers 
significant risks to patients, as it may predispose to severe cardio-
vascular events, such as heart attack and stroke (4, 5). The identifi-
cation of new therapeutic targets downstream of COX inhibition 
may therefore provide a rational and promising strategy for the 
development of more specific and better-tolerated analgesics.
Prostaglandin E2 (PGE2) is a key factor in the generation of 
exaggerated pain sensations evoked by inflammation (6). It 
exerts its cellular effects through 4 different G protein–coupled 
receptors encoded by separate genes, termed EP1 through EP4 
(7). These receptors differ in their tissue distribution, signaling 
pathways, and physiological functions, which should allow the 
treatment of inflammatory pain with much greater specificity 
than currently achievable by the global blockade of PG synthe-
sis via COX inhibitors. Studies performed either in mutant mice 
lacking individual PG receptors (8–10) or with synthetic PG 
receptor ligands (e.g., refs. 11, 12) have not yet provided a coher-
ent picture of which EP receptors are responsible for inflamma-
tory pain sensitization. This is partly due to the fact that PGs 
facilitate nociception at different levels of integration (13). They 
do not only sensitize peripheral nociceptors (14–16) but can also 
lead to changes in the central, particularly spinal, processing of 
nociceptive input (17, 18). It is hence still unclear which PGs and 
which PG receptors mediate pain sensitization in the periphery 
and in the spinal cord, respectively, and to what extent the 2 sites 
contribute to inflammatory hyperalgesia.
During recent years several cellular candidate pathways have 
been identified that are possibly involved in PG-induced pain sen-
sitization in the periphery (14, 16) and in the CNS (19, 20). Our 
own group has suggested that PGE2 facilitates spinal nociceptive 
transmission through blockade of inhibitory glycine receptors 
located in the superficial layers of the spinal cord dorsal horn 
(20, 21). This blockade would lead to a disinhibition of dorsal 
horn neurons and subsequently facilitate the propagation of 
nociceptive signals through the spinal cord to higher CNS areas. 
We now demonstrate that mice deficient in the EP2 receptor 
(EP2–/– mice) not only completely lack PGE2-mediated inhibition 
of glycinergic neurotransmission but also show no pain sensitiza-
tion after intrathecal PGE2 injection. In contrast to spinal pain 
sensitization, peripheral pain sensitization evoked by subcutane-
ously injected PGE2 was retained in EP2–/– mice. In the zymosan 
A model of peripheral inflammation, EP2–/– mice exhibited an 
almost normal early hyperalgesia. However, unlike WT and EP3–/– 
mice, EP2–/– mice completely recovered from sensitization within 
2 days, indicating that spinal processes dominate peripheral ones 
during prolonged inflammatory pain sensitization.
Nonstandard abbreviations used: ACSF, artificial cerebrospinal fluid; BAC, bacte-
rial artificial chromosome; EGFP, enhanced GFP; GlyT2, glycine transporter type 2; 
IPSC, inhibitory postsynaptic current.
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Results
Spinal hyperalgesic properties of different PGs. In a first series of experi-
ments, we determined the ability of different PGs to induce spinal 
pain sensitization. We injected small amounts (0.2 nmol per mouse) 
of PGE2, PGD2, PGF2α, PGI2, or vehicle (1% ethanol) intrathecally 
(i.e., into the spinal canal) in WT mice and monitored changes in 
their nociceptive reactions upon exposure to a defined noxious 
heat stimulus or to mechanical stimulation with von Frey filaments 
(Figure 1). Following intrathecal injection of PGE2, pronounced 
thermal hyperalgesia developed within less than 30 minutes and 
recovered slowly over about 6 hours (see also Figure 2). At the peak 
of the response (60 minutes after injection), paw withdrawal laten-
cies upon thermal stimulation decreased from 16.4 ± 0.9 seconds 
to 8.3 ± 1.4 seconds (mean ± SD, n = 6) (Figure 1A). All other PGs 
were without significant effect. Similar results were obtained for 
mechanical stimulation (Figure 1B). PGE2 increased mechanical 
sensitivity significantly over the entire range of stim-
ulation strengths tested (1–90 mN). PGD2, PGF2α, 
and PGI2 were without effect (Figure 1, C–F).
EP2 receptors mediate the spinal hyperalgesic effect of 
PGE2. Among the 4 subtypes of EP receptors, expres-
sion in the spinal cord is best documented for the 
EP2 and EP3 subtypes (22–24). We therefore deter-
mined the contribution of these receptors to spinal 
PGE2-induced hyperalgesia. Under base-line condi-
tions, WT mice and EP2 receptor– and EP3 receptor–
deficient mice (EP2–/– and EP3–/– mice) showed vir-
tually identical sensitivities to noxious heat (P > 0.5, 
ANOVA followed by Scheffe’s post hoc test, n = 6 
each) and mechanical stimulation (P > 0.19) (Figure 2, 
A and B) and no abnormalities in the expression of 
markers of the spinal nociceptive system (Supple-
mental Figure 1; available online with this article; 
doi:10.1172/JCI200523618DS1). Following intrathe-
cal injection of PGE2, EP3–/– mice developed thermal 
and mechanical hyperalgesia indistinguishable from 
that in WT mice (Figure 2, A–C and E). In contrast, 
PGE2 failed to induce thermal or mechanical sen-
sitization in EP2–/– mice. The defect in mechanical 
sensitization occurred throughout the entire range 
of stimulation strengths tested (Figure 2D).
In contrast to spinal hyperalgesia, peripheral sen-
sitization was retained in EP2–/– (and EP3–/–) mice 
(Figure 3). Thermal sensitization in EP2–/– and 
EP3–/– mice evoked by local s.c. injection of 0.5 nmol 
PGE2 into the left hind paw was indistinguishable 
from that seen in WT mice. Mechanical sensitiza-
tion was reduced in EP2–/– mice by 48% ± 8.2% (n = 6), 
which suggests that mechanical pain sensitization 
was partially mediated by peripheral EP2 receptors. 
EP3–/– mice behaved normally in both tests.
Contribution of EP2 receptors to spinal hyperalgesia 
evoked by peripheral inflammation. The lack of spinal 
PGE2-mediated pain sensitization in EP2–/– mice 
in the presence of retained peripheral sensitization 
allowed us to determine the relative contributions of 
spinal versus peripheral processes to inflammatory 
pain sensitization. We therefore analyzed the differ-
ent types of mice in the zymosan A model (Figure 4). 
In these experiments the yeast extract zymosan A 
(0.06 mg in 20 μl PBS) was injected s.c. into the plantar side of the 
left hind paw, a procedure that induces inflammation and a subse-
quent increase in spinal COX-2 expression (25). WT mice and the 
2 types of mutant mice exhibited virtually identical paw swelling 
(P > 0.69, ANOVA followed by Scheffe’s post hoc test, at 6 hours 
after zymosan A injection) (Figure 4A) and spinal COX-2 induction 
determined by real-time RT-PCR (Figure 4B). However, thermal 
and mechanical hyperalgesia developed differently in the different 
types of mice. In WT mice, paw withdrawal latencies decreased from 
17.0 ± 0.3 seconds to 8.5 ± 1.2 seconds (n = 6) within 4 hours, 
remained stable for about 24 hours, and then recovered slowly within 
7 days. Initially (at 2 hours), thermal and mechanical sensitization in 
EP2–/– mice was very similar to that seen in WT mice. However, from 
4 hours onward EP2–/– mice recovered much faster from hyperalge-
sia, and a significant difference between WT mice and EP2–/– mice 
became obvious at 4–6 hours. From day 3–4 onward, thermal hyper-
Figure 1
Thermal and mechanical sensitization by different spinally applied PGs. (A) Chang-
es in paw withdrawal latency (mean ± SD, n = 4–6) upon exposure of mice to a 
defined radiant heat stimulus after intrathecal injection of PGE2, PGD2, PGI2, PGF2α 
(0.2 nmol per mouse), or vehicle (1% ethanol). (B) Changes in nociceptive reactions 
(percent maximum possible response, mean ± SD, n = 4–6; for details see Methods) 
upon mechanical stimulation with an 8-mN von Frey filament after intrathecal PG 
injection. The legend in B refers to A and B. (C–F) Stimulus-response curves for 
mechanical stimulation obtained before and 60 minutes after intrathecal injections 
of the different PGs (or vehicle) (same mice as in B). ***P < 0.001 (ANOVA followed 
by Scheffe’s post hoc test, n = 6 each).
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algesia in EP2–/– mice became statistically indistinguishable (P > 0.05, 
ANOVA) from that in vehicle-injected control mice. Similar effects 
were obtained for mechanical hyperalgesia (Figure 4, E and F).
We next tested whether the fast recovery from hyperalgesia seen in 
EP2–/– mice was due to the defect in spinal sensitization. Indeed, the 
time point at which sensitization in EP2–/– mice started to signifi-
cantly differ from that in WT mice correlated well with the induction 
of COX-2 mRNA and PGE2 concentrations in the spinal cord dorsal 
horn (Figures 4B and 5B, respectively). To verify the spinal origin of 
the delayed sensitization, we tested the effect of COX-2 inhibition in 
WT mice at different time points after zymosan A injection (Figure 5). 
Intrathecal injection of the COX-2–specific inhibitor celecoxib 
(2 or 20 nmol) caused only a modest antinociception at 2 hours after 
zymosan A injection, while at 6 hours and after 2 days a significant, 
dose-dependent and reversible antinociception was obtained. Inter-
estingly, the reduction in thermal hyperalgesia achieved with intra-
thecal celecoxib was very similar to that resulting from the disruption 
of the EP2 receptor gene (compare Figure 4, C and D, and Figure 5).
EP2 receptor activation disinhibits superficial dorsal horn neurons. In a 
final set of experiments, we addressed the molecular mechanisms 
responsible for EP2 receptor–dependent spinal hyperalgesia. It was 
indeed the EP2 receptor subtype that was responsible for the inhibi-
tion of glycinergic neurotransmission by PGE2 (Figure 6), a phenom-
enon that we have shown underlies spinal inflammatory hyperalgesia 
(21). Whole-cell patch-clamp recordings of inhibitory postsynaptic 
currents (IPSCs) mediated by glycine were made from neurons locat-
ed in the superficial spinal cord dorsal horn, where most nociceptive 
afferent nerve fibers terminate. As shown previously, in WT mice PGE2 
(1 μM) reduced the amplitudes of glycinergic IPSCs by 39.9% ± 5.0% 
(mean ± SEM, n = 8). This inhibition was absent in EP2–/– mice 
(–8.5% ± 6.5%, n = 9) but remained largely unchanged in EP3–/– mice 
(29.7% ± 6.1%, n = 8), demonstrating that the reduction of glycinergic 
IPSCs by PGE2 was exclusively mediated through EP2 receptors.
Because inhibition of glycinergic neurotransmission by PGE2 
occurs in the majority (about 80%) of dorsal horn neurons but not 
in all of them (20), we tested whether this inhibition was restricted to 
a defined subset of neurons (Figure 7). To address this question, we 
recorded glycinergic IPSCs in spinal cord slices obtained from bac-
terial artificial chromosome (BAC) transgenic mice, which express 
Figure 2
Thermal and mechanical 
hyperalgesia evoked by PGE2 
in EP2–/– and EP3–/– mice. (A 
and B) Paw withdrawal laten-
cies (mean ± SD, n = 6 each) 
upon radiant heat stimulation 
(A) and nociceptive reaction 
scores (mean ± SD, n = 6 each) 
upon mechanical stimulation 
with an 8-mN von Frey fila-
ment (B) after intrathecal (i.t.) 
injection of PGE2 (0.2 nmol). 
Nociceptive sensitization in 
EP2–/– mice was significantly 
less than in WT mice at all time 
points between 1 and 5 hours 
(P < 0.001, ANOVA followed by 
Scheffe’s post hoc test, n = 6 
each). (C–E) Stimulus-response 
curves for mechanical stimula-
tion obtained before and after 
intrathecal injections of PGE2 in 
WT mice and EP2–/– and EP3–/– 
mice (same mice as in B).
Figure 3
Peripheral pain sensitization. Thermal sensitization (paw withdrawal 
latencies upon exposure to noxious heat) (A) and mechanical sen-
sitization (reaction scores evoked by stimulation with an 8-mN von 
Frey filament, mean ± SD, n = 6 each) (B) at different time points 
after s.c. injection of PGE2. EP2–/– mice exhibited significantly less 
mechanical sensitization than WT mice at time points from 0.5–1.5 
hours (P < 0.01–0.05, ANOVA followed by Scheffe’s post hoc test).
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enhanced GFP (EGFP) specifically in glycinergic neurons under the 
control of the neuronal glycine transporter type 2 (GlyT2) promoter 
(26). Both glycinergic and nonglycinergic neurons received glyciner-
gic input of similar amplitude (451 ± 104 pA and 498 ± 147 pA for 
EGFP-positive and -negative neurons, respectively, n = 10 each) and 
with similar kinetics (rinse time = 1.69 ± 0.19 and 1.96 ± 0.16 mil-
liseconds, and decay time = 17.8 ± 3.1 and 14.7 ± 2.0 milliseconds, 
in EGFP-positive and -negative neurons, respectively) (Figure 7, 
A and B). However, significant (at least 10%) inhibition of glycinergic 
IPSCs by PGE2 occurred much more frequently in nonglycinergic 
neurons (8 of 10), presumed to be glutamatergic, than in glycinergic 
neurons (2 of 10, P < 0.01, χ2 test).
Discussion
Although PGE2 has long been recognized as a lipid mediator 
produced in many organs throughout the body in response to 
a variety of physiological and pathological stimuli, the contri-
bution of individual EP receptor subtypes to defined functions 
of PGE2 has long remained elusive. This question is of major 
therapeutic relevance, because the majority of desired and 
unwanted effects of COX inhibitors are due to the blockade of 
PGE2 production. Both the generation of genetically modified 
mice lacking the different EP receptor subtypes and the develop-
ment of EP receptor subtype–specific ligands have provided new 
insights (for a review see ref. 27). Using a genetic approach, we 
now have identified the EP2 receptor subtype as a key signaling 
element in spinal inflammatory hyperalgesia. The present study 
thus adds to the growing evidence that the targeting of indi-
vidual PG receptor subtypes permits the separation of desired 
and unwanted effects of NSAIDs (28).
Moreover, our results attribute to PGE2 a dominant role in spi-
nal pain sensitization. Although other PGs have been implicated in 
this process (e.g., refs. 29, 30), our findings correlate well with the 
selective upregulation of microsomal PGE2 synthase-1 (mPGES-1) 
in the spinal cord after peripheral inflammation (31) and dimin-
ished nociceptive responses in mPGES-1–deficient mice (32). More 
controversial is the contribution of the different EP receptor sub-
types to pain sensitization in the spinal cord. Indeed, several reports 
suggested a critical role of spinal EP1 receptors in PGE2-mediated 
pain sensitization. Although expression of EP1 receptors has not 
been demonstrated for intrinsic spinal cord neurons (33), they are 
found on the central (spinal) terminals of primary nociceptive nerve 
fibers (34), where they might facilitate the release of excitatory neu-
rotransmitters (35). However, most of the behavioral studies rely 
on the intrathecal injection of the EP1 receptor antagonists (e.g., 
ONO-8711; refs. 12, 36). Their specificity in these in vivo experi-
ments is difficult to judge, because the actual concentration in the 
spinal cord tissue is unknown in these studies.
Our results provide new insights into the neurophysiological basis 
of spinal inflammatory pain sensitization. We have previously dem-
onstrated that PGE2 reduces inhibitory (strychnine-sensitive) gly-
cinergic neurotransmission in the spinal cord dorsal horn (20, 21). 
Two sets of experiments now demonstrate that activation of this 
pathway by EP2 receptors is the dominant mechanism of spinal 
Figure 4
Paw swelling, spinal COX-2 mRNA induction, and nociceptive sensitization after zymosan A injection. (A) Percent increase in paw weight 
(mean ± SD, n = 6 each) after s.c. injection of 0.06 mg zymosan A into the left hind paw. (B) x-fold increase (mean ± SD, n = 6 each) in spinal 
COX-2 mRNA expression. All 3 types of mice exhibited a significant increase in COX-2 mRNA expression at 6 hours after zymosan A injec-
tion (P < 0.05, ANOVA followed by Scheffe’s post hoc test, n = 4–6 each). (C–F) Time course of thermal (C and D) and mechanical (E and F) 
sensitization (mean ± SD, n = 6 each) after zymosan A injection. D and F show the same data as C and E on a different time scale. Thermal 
sensitization in EP2–/– mice was significantly different from that in WT mice at all time points from 4 hours after zymosan A injection, and 
mechanical stimulation in EP2–/– mice was significantly different from that in WT mice at all time points from 6 hours after zymosan A injection. 
**P < 0.01, ***P < 0.001 (ANOVA followed by Scheffe’s post hoc test).
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inflammatory pain sensitization. First, EP2–/– mice were protected 
from spinal hyperalgesia elicited both by intrathecal PGE2 injection 
and by zymosan A–induced peripheral inflammation, and second, 
inhibition of glycinergic neurotransmission by PGE2 was absent in 
EP2–/– mice. In these respects the phenotype of the EP2–/– mice very 
much resembles that of mice deficient in the glycine receptor α3 
subunit (21), which also lack PGE2-mediated inhibition of glycin-
ergic neurotransmission. Our experiments with the BAC transgenic 
mice expressing EGFP in glycinergic interneurons have now dem-
onstrated that the inhibitory effect of PGE2 on glycinergic synaptic 
inhibition is restricted to nonglycinergic interneurons. The major-
ity of the neurons are most likely excitatory and use L-glutamate as 
their fast neurotransmitter. PGE2 thus preferentially impairs the 
glycinergic inhibitory control of excitatory interneurons. This pro-
motes the propagation of nociceptive signals through the spinal 
cord to higher CNS areas and thereby gives rise to the development 
of spinal hyperalgesia. This mechanism may also explain why COX 
inhibitors are primarily antihyperalgesic agents and do not exert a 
general analgesic activity as opioids do.
Experiments with the COX-2–selective inhibitor celecoxib indicate 
that the PGE2 responsible for spinal EP2 receptor activation comes 
from COX-2, which is induced in the spinal cord dorsal horn in 
response to peripheral inflammation (this study and refs. 17, 37). 
The time course of the analgesic action of celecoxib, with only very 
little or no analgesic effect during early hyperalgesia (2–4 hours after 
zymosan A injection) but pronounced analgesia at later stages, nicely 
corresponds to the time course of spinal PGE2 production and per-
fectly matches the fast recovery from inflammatory hyperalgesia in 
EP2–/– mice (compare Figures 4 and 5). The time course of spinal 
PGE2 production also explains why PGE2 caused very fast responses 
after intrathecal injection and in the electrophysiological experi-
ments, while EP2 receptor–dependent pain sensitization required 
more than 4 hours for full expression after zymosan A injection. 
Our experiments hence demonstrate that PGE2-dependent changes 
in the spinal processing of nociceptive input develop within a few 
hours and become the dominant source of inflammatory hyperal-
gesia, which can significantly outlast the peripheral symptoms of 
inflammation (compare Figures 4A and 4B). Other, EP2 receptor–
independent mechanisms of inflammatory hyperalgesia appear to 
be of major relevance only early in the development of inflammation 
and are most likely peripheral in nature. They probably include the 
activation of EP1 or prostacyclin (IP) receptors, as demonstrated by 
the deficits in peripheral inflammatory pain sensitization observed 
in EP1 receptor– or IP receptor–deficient mice (8, 10). It is appar-
ent from our study that neither EP2 nor EP3 receptors contribute to 
paw swelling or peripheral thermal sensitization. The specific loss of 
spinal inflammatory pain sensitization in EP2–/– mice correlates well 
with the expression profile of EP receptors in the nervous system. 
While in intrinsic spinal cord neurons EP receptor expression is best 
documented for the EP2 subtype (22), EP1, EP3, and EP4 are pre-
dominant in primary nociceptive afferents (34). Nevertheless, part 
of the peripheral component of mechanical sensitization is appar-
ently mediated by EP2 receptors and may originate from facilitation 
of tetrodotoxin-resistant Na+ channels (14), which are of particular 
relevance to the sensation of noxious mechanical stimuli (38).
Figure 5
Contribution of COX-2–derived PGs to spinal inflammatory pain sensi-
tization. (A) Paw withdrawal latencies (mean ± SD, n = 6 each) versus 
time after zymosan A injection (0.06 mg s.c. into the left hind paw). At 
the times indicated (arrows), 2 or 20 nmol celecoxib was injected intra-
thecally (n = 6–7). (B) Spinal PGE2 concentrations (mean ± SEM) after 
zymosan A injection (n = 4–5). *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 6
Effects of PGE2 on glycinergic inhibitory neurotransmission in the spinal 
cord dorsal horn. (A) Averages of 10 glycinergic IPSCs recorded from 
superficial spinal cord dorsal horn neurons before (black) and during (red) 
application of PGE2 (1 μM) in WT, EP2–/–, and EP3–/– mice. (B) Statistical 
analysis (mean ± SEM, n = 8–10) of IPSC inhibition by PGE2. Analysis 
includes PGE2-responsive and nonresponsive neurons. ***P ≤ 0.001.
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In summary, our results attribute to spinal EP2 receptors a dom-
inant role in the generation of inflammatory pain. They point 
to a novel, more specific, and probably better-tolerated analgesic 
strategy employing EP2 receptor antagonists as centrally acting, 
nonopioidergic, antihyperalgesic agents.
Methods
Mice. Behavioral and electrophysiological experiments were performed in 
EP2 (ptger2) and EP3 (ptger3) receptor-deficient mice (EP2–/– and EP3–/– 
mice) (39, 40), which had been backcrossed to the C57BL/6 background 
for at least 10 generations, and in the corresponding WT mice (C57BL/6). 
Electrophysiological experiments were in addition performed in BAC 
transgenic mice expressing EGFP under the control of the GlyT2 (slc6a5) 
promoter in glycinergic interneurons (26). The genotype of all mice ana-
lyzed was verified by PCR as described previously (39, 40).
Behavioral testing. Six- to eight-week-old male mice were used for behav-
ioral testing. Mice were kept in the test cages for 1 day to allow accom-
modation. On day 2, each mouse was tested several times to obtain base-
line paw withdrawal latencies and mechanical stimulus-response curves. 
Paw withdrawal latencies upon exposure to defined radiant heat stimuli 
were measured using a commercially available apparatus (plantar test; 
Ugo Basile Biological Research Apparatus Co.). Mechanical sensitivity was 
determined using von Frey filaments and scored 0, no response; 1, paw 
withdrawal; or 2, immediate flinching of the stimulated paw (41). Three 
independent measurements were averaged, and a normalized response 
score (0–100%) was calculated. Separate groups of mice were used for ther-
mal and mechanical testing. In all behavioral experiments, the observer was 
blind to the genotype of the mice. For intrathecal injections, PGE2 was dis-
solved in 1% ethanol, 99% artificial cerebrospinal fluid (ACSF), and injected 
in a total volume of 2 μl. Intrathecal injections were made into the lower 
lumbar spinal canal using a Hamilton Co. syringe (for details see ref. 42). 
For s.c. injections, PGE2 was dissolved in 0.1% DMSO, 99.9% PBS, and 
injected in a total volume of 5 μl. In both cases vehicle did not cause noci-
ceptive sensitization. Because of its poor solubility, celecoxib was dissolved 
in 20% DMSO, 80% ACSF, and injected in a total volume of 10 μl. Zymosan 
A (0.06 mg in 20 μl PBS) was injected into the plantar side of the left hind 
paw. All behavioral experiments were performed in an air-conditioned 
room (22°C). After the tests the mice were killed by CO2 inhalation. All 
animal experiments were performed in accordance with the institutional 
guidelines of the University of Erlangen-Nürnberg and of the European 
Communities Council Directive (86/609/EEC) and were approved by the 
animal welfare committee of the Regierung von Unterfranken. Permission 
was obtained from the local government (Regierung von Mittelfranken, 
reference no. 621-2531.31-17/03).
Quantification of COX-2 mRNA. Mice were killed by decapitation, and tis-
sue samples of the spinal cord segment L4 were snap-frozen in 800 μl of 
lysis buffer (QIAGEN GmbH) and stored at –70°C. After homogeniza-
tion, RNA was isolated using an RNeasy kit (QIAGEN GmbH). Real-time 
RT-PCR was used to quantify actin and COX-2 mRNA. TaqMan probes 
used were as follows: actin, 5′-(6FAM)TATGCTC(TAMRA)TCCCTCAC
GCCATCCTGCT-3′; COX-2, 5′-(6FAM)CTACCATGGTC(TAMRA)TCC
CCAAAGATAGCATCA-3′. Primers used were as follows: actin, forward 
5′-TCACCCACACTGTGCCCATCTACGA-3′, reverse 5′-GGATGCCACAG-
GATTCCATACCCA-3′; COX-2, forward 5′-TTTGTTGAGTCATTCAC-
CAGACAGAT-3′, reverse 5′-CAGTATTGAGGAGAACAGATGGGATT-3′ 
(for PCR conditions see ref. 25).
PGE2 measurements. PGE2 measurements were taken using the Correlate 
EIA Kit (Assay Designs Inc.). The thoracolumbar segment of the spinal 
cord was removed and transferred into 99.5% methanol (500 μl), stored for 
24 hours at –20°C, and then shaken for 2 hours at room temperature. The 
spinal cord tissue was then removed, and the methanol was evaporated. 
The remaining pellet was dissolved in 100 μl of enzyme immunoassay 
buffer. Measurement was done using an ELISA reader (DIAS microplate 
reader; Dynatech Laboratories) with an absorbance maximum at 405 nm.
Electrophysiological recordings in spinal cord slices. Ten- to fourteen-day-old 
mice of both sexes were killed under ether narcosis by decapitation (for 
details see ref. 20). Transverse slices, 250 μm thick, of the lumbar spi-
nal cord, were prepared as described previously. Whole-cell patch-clamp 
recordings were performed from neurons located in lamina II of the spinal 
cord dorsal horn. Neurons were visually identified using the infrared gradi-
ent contrast technique coupled to a video microscopy system. Slices were 
continuously superfused with external solution, which contained (in mM) 
125 NaCl, 26 NaHCO3, 1.25 NaH2PO4, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 glu-
cose (pH 7.30, 315 mosm/l) and was bubbled with 95% O2, 5% CO2. Patch 
pipettes (4–5 MΩ) were filled with internal solution containing (in mM) 
130 K-gluconate, 20 KCl, 2 MgCl2, 0.05 EGTA, 3 Na-ATP, 0.1 Na-GTP, 
10 Na-HEPES (pH 7.30). Five millimolar QX-314 was added to the internal 
solution to block voltage-activated sodium currents. Postsynaptic current 
responses were elicited at a frequency of 1 per 15 seconds by extracellular 
electrical field stimulation (100 microseconds, 3–10 V) and recorded at 
room temperature and at a holding potential of –80 mV. Glycinergic IPSCs 
were isolated using 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 10 μM), 
Figure 7
Whole-cell patch-clamp recordings from visually identified glycinergic 
neurons in the superficial mouse spinal cord dorsal horn. (A) EGFP-
expressing neurons in the superficial layers of the mouse spinal cord 
dorsal horn, visualized in a 250-μm-thick slice prepared from a transgen-
ic mouse expressing EGFP in glycinergic neurons under the control of 
the GlyT2 promoter. (B) Averages of 10 consecutive glycinergic IPSCs 
recorded from an EGFP/GlyT2-negative and an EGFP/GlyT2-positive 
neuron under control conditions, in the presence of PGE2 (1 μM), and 
after its removal. (C) Time course of inhibition of glycinergic IPSCs by 
PGE2 in EGFP-positive and -negative neurons. (D) Average inhibition 
(mean ± SEM) of glycinergic IPSCs by PGE2 in EGFP-positive and -neg-
ative neurons (n = 10 each). Both PGE2-responsive and nonresponsive 
neurons were included for the statistics. ***P < 0.001 (unpaired t test).
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D-2-amino-5-phosphonovaleric acid (D-APV; 50 μM), and bicuculline 
(10 μM). Short hyperpolarizing voltage steps to –90 mV were applied in 
1-minute intervals to monitor input and access resistance. PGE2 (1 μM) 
was applied by bath perfusion at a rate of 1–2 ml/min.
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